256 related articles for article (PubMed ID: 28886476)
1. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.
Ravaud A; Gomez-Roca C; Picat MQ; Digue L; Chevreau C; Gimbert A; Chauzit E; Sitta R; Cornelis F; Asselineau J; Aziza R; Daste A; Quemener C; Baud J; Bikfalvi A; Pedenon-Périchout D; Doussau A; Molimard M; Delord JP
Eur J Cancer; 2017 Nov; 85():39-48. PubMed ID: 28886476
[TBL] [Abstract][Full Text] [Related]
2. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
3. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
[TBL] [Abstract][Full Text] [Related]
5. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
6. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
8. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.
Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H
Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
Rini BI; Escudier B; Hariharan S; Roberts WG; Tarazi J; Rosbrook B; Askerova Z; DeAnnuntis LL; Motzer RJ
Clin Genitourin Cancer; 2015 Dec; 13(6):540-7.e1-7. PubMed ID: 26320662
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
11. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
15. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
[TBL] [Abstract][Full Text] [Related]
16. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Voss MH; Bhatt RS; Plimack ER; Rini BI; Alter RS; Beck JT; Wilson D; Zhang X; Mutyaba M; Glasser C; Attie KM; Sherman ML; Pandya SS; Atkins MB
Clin Cancer Res; 2017 Jul; 23(14):3557-3565. PubMed ID: 28031424
[No Abstract] [Full Text] [Related]
17. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Michaelson MD; Gupta S; Agarwal N; Szmulewitz R; Powles T; Pili R; Bruce JY; Vaishampayan U; Larkin J; Rosbrook B; Wang E; Murphy D; Wang P; Lechuga MJ; Valota O; Shepard DR
Oncologist; 2019 Sep; 24(9):1151-e817. PubMed ID: 31171735
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
[TBL] [Abstract][Full Text] [Related]
19. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Sharma S; Abhyankar V; Burgess RE; Infante J; Trowbridge RC; Tarazi J; Kim S; Tortorici M; Chen Y; Robles RL
Ann Oncol; 2010 Feb; 21(2):297-304. PubMed ID: 19940012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]